Finding Inhibitors for Chikungunya Virus
Author Information
Author(s): Navarro Hernan, Scott John E., Smith Ginger R., Ghiabi Pegah, Gibson Elisa, Loppnau Peter, Harding Rachel J., Hossain Mohammad Anwar, Bose Muthu Ramalingam, Pearce Kenneth H., Merten Eric M., Willson Timothy M., Brown Peter J.
Primary Institution: Department of Pharmaceutical Sciences, Biomanufacturing Research Institute and Technology Enterprise (BRITE), North Carolina Central University, Durham, NC, USA.
Hypothesis
Can we identify compounds that inhibit the ATPase activity of Chikungunya virus nsP2?
Conclusion
Several inhibitors of CHIKV nsP2 ATPase activity were identified, with a spiropiperidine chemotype among the most potent.
Supporting Evidence
- 30 confirmed actives were identified from the primary assay.
- Nine compounds showed IC50 < 10 μM in the secondary assay.
- The most potent compound had an IC50 of 0.6 μM.
Takeaway
Researchers looked for medicines that can stop the Chikungunya virus from making copies of itself, and they found some promising candidates.
Methodology
A high-throughput screening of a library of 48,712 compounds was conducted using an ATPase assay to identify potential inhibitors.
Limitations
Further studies are needed to confirm the mechanism of action of the identified inhibitors.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website